NCT06498362

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children: Multicenter Retrospective Study on 151 Children Over Three Months Old

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 151 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 3 Months – 17 Years
• Healthy volunteers: Not accepted

Summary

Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus

Conditions

• Epilepsy in Children

Timeline

• Start date: 2023-11-16
• Primary completion: 2025-05-01
• Completion: 2025-05-16
• First posted: 2024-07-12
• Last updated: 2024-07-12

Locations

1 site across 1 country: France